Argus Research Maintains Elevance Health(ELV.US) With Buy Rating, Raises Target Price to $465
A Quick Look at Today's Ratings for Elevance Health(ELV.US), With a Forecast Between $478 to $585
Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges
Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook With Potential Upside
Deutsche Bank Cuts Elevance Health Price Target to $463 From $465, Maintains Buy Rating
RBC Capital Reiterates Outperform on Elevance Health, Maintains $478 Price Target
Jefferies Adjusts Price Target on Elevance Health to $488 From $461, Maintains Buy Rating
Guggenheim Reiterates Buy on Elevance Health, Maintains $518 Price Target
Elevance Health Is Maintained at Overweight by Barclays
Elevance Health Price Target Raised to $522.00/Share From $512.00 by Barclays
Elevance Health Analyst Ratings
Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves
Elevance Health: Hold Rating Amid Medicare Cost Pressures and Regulatory Risks
Barclays Adjusts Elevance Health Price Target to $522 From $512, Keeps Overweight Rating
Research Alert: Elevance Health Reports Q1 Results, Beats Expectations On Top-line Growth
Truist Financial Initiates Elevance Health(ELV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Eli Lilly & Co (LLY) and Elevance Health (ELV)
Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)
Leerink Partners Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $463
Elevance Health: Buy Rating Affirmed Amid Favorable Outlook and Strategic Adjustments